
FDA Approves Maralixibat to Treat Rare Pediatric Liver Disease
Maralixibat is the first treatment approved for cholestatic pruritus in patients with Alagille syndrome who are 1 year or older.
The FDA has approved the first treatment for cholestatic pruritus in patients with Alagille syndrome (ALGS) who are 1 year or older. Maralixibat (Livmarli) is an orally administered, once-daily ileal bile acid transporter inhibitor from Mirum Pharmaceuticals Inc.
ALGS is a rare genetic disorder that causes a bile buildup in the liver and affects 2000 to 2500 children in the United States.
“Children with Alagille syndrome suffer from cholestatic pruritus, which is serious, unremitting, and debilitating. Their sleep is disrupted, and they endure bleeding and scarring of the skin due to unrelenting scratching,” Binita M. Kamath, MBBChir, pediatric hepatologist, The Hospital for Sick Children in Toronto, Ontario, Canada,
The approval of maralixibat was based on the results of the pivotal ICONIC study, as well as 5 years of data from supportive studies.
ICONIC was a randomized, controlled long-term phase 2B study. The
There were a total of 31 children (mean age, 5.4 years) enrolled in the ICONIC study. First, patients were treated for 18 weeks with maralixibat before being randomized to receive either placebo (n = 16) or maralixibat (n = 13) for 4 weeks. After this randomized withdrawal period, all patients were treated with maralixibat for the remainder of the 48 weeks.
Treatment-emergent adverse events (TEAEs) were reported in 30 of the patients. Only 4 patients had serious TEAEs, which were considered to be unrelated to maralixibat, and 2 TEAEs leading to discontinuation, which were also unrelated to the therapy. Diarrhea and abdominal pain were the most frequent TEAEs.
“Until now, patients have had limited-to-no treatment options to address the severe and unrelenting itch that significantly impacts both patients and their families,” said Roberta Smith, president, Alagille Syndrome Alliance, and an ALGS mom.
Mirum has submitted an application for maralixibat with the European Medicines Agency.
“The six-year event-free survival data, coupled with the previously presented ICONIC data, provides a catalyst to accelerate our ALGS submission,”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.